Finvest
VRNA Biotech · Acquired · COPD · Single drug · Thesis updated June 14, 2026

Ohtuvayre worked, then Merck bought it

01 Running thesis

The stock story ended in a sale

Verona's internal thesis changed on July 8, 2025, when the company signed a definitive agreement for Merck to buy it for about $10 billion. Before that, the debate was whether Ohtuvayre could become a large COPD drug on its own. After that, the public stock case became a deal case.

The deal had strong support from the operating numbers. Ohtuvayre net product sales reached $102.9 million in Q2 2025. Verona also reported $11.9 million of net income for that quarter, its first quarterly profit after years of losses.

Public sources after Verona's Q2 2025 filing say the deal closed on October 7, 2025. That means the old bull case, closing the Merck deal, has largely played out. The main caution for a reader is that VRNA may still appear in old quote pages even though Merck says Verona became a wholly owned subsidiary and its ADSs no longer trade on Nasdaq.

If the deal had failed, the bear case would have been sharp. Verona still had a limited commercial history, a single approved product, high operating costs, and an accumulated deficit of $567.1 million as of June 30, 2025. That standalone risk matters less now, but it explains why the Merck closing was the key event.

Oct 2025▲Merck said it completed the acquisition of Verona. That changed the page from a merger-arbitrage story into a completed-sale record.
Aug 2025▲Verona's Q2 2025 filing showed $102.9 million of Ohtuvayre net product sales and $11.9 million of net income. The Merck agreement became the main investment event.
Apr 2025▲Q1 2025 Ohtuvayre sales reached $71.3 million, which made the launch look much more credible. The loss narrowed, but SG&A stayed high.
Feb 2025→The 2024 10-K confirmed $42.3 million of Ohtuvayre net product sales after launch. It also showed heavy launch spending and a $173.4 million net loss for the year.
Nov 2024▲Verona booked its first Ohtuvayre product sales, $5.6 million in Q3 2024. The company also showed the expected cost jump from building a sales force.
Aug 2024▲The initial page view began after FDA approval and U.S. launch of Ohtuvayre. At that point, the core question was whether one new COPD drug could support a full commercial company.
02 Business model

One COPD drug, sold in the U.S.

Verona made money mainly by selling Ohtuvayre in the United States. Ohtuvayre is an inhaled, nebulized maintenance treatment for adults with COPD, a long-term lung disease that makes breathing hard. The FDA approved it on June 26, 2024, and Verona launched it in August 2024.

The launch ramp was fast. Ohtuvayre generated $5.6 million of net product sales in Q3 2024, $42.3 million for the year ended December 31, 2024, $71.3 million in Q1 2025, and $102.9 million in Q2 2025.

Outside the United States, Verona used licensing. Its key example was Nuance Pharma for Greater China. In June 2025, Verona gave notice that it wanted to buy back those rights, and Nuance disputed that notice.

The weak point in the standalone model was cost. SG&A was $149.8 million in 2024 as Verona built a field sales team and launched Ohtuvayre. R&D was $44.6 million in 2024 as it started new Phase 2 studies. A fast launch helped, but the company still had a long loss history before Q2 2025.

03 Product portfolio

All roads lead to ensifentrine

Growth engine

Ohtuvayre for COPD

Ohtuvayre is the approved nebulized form of ensifentrine for adult COPD maintenance treatment. It was Verona's only approved product and the reason Merck bought the company.

Option

Ensifentrine plus glycopyrrolate

Verona started a Phase 2 dose-ranging trial in Q3 2024 to support a fixed-dose combination with glycopyrrolate, a LAMA drug used to relax airway muscles. The goal was to build a stronger COPD franchise around ensifentrine.

Option

Nebulized ensifentrine for NCFBE

A Phase 2 trial began in Q3 2024 for non-cystic fibrosis bronchiectasis, another chronic lung disease. This could have widened the use of the same molecule beyond COPD.

Option

Dry powder inhaler ensifentrine

Verona also studied a dry powder inhaler version in Phase 2 for COPD. A handier device could matter because not every patient wants or needs a nebulizer.

Option

pMDI ensifentrine

The pressurized metered-dose inhaler version was another Phase 2 formulation path. It was aimed at giving patients a familiar inhaler format.

04 Business segments

Reported as one business

Respiratory therapeutics100%growing fast
Other disclosed operating segments0%flat

Verona reported one integrated respiratory therapeutics business, not separate operating segments. For Q2 2025, the practical revenue story was Ohtuvayre product sales, with no other operating segment disclosed.

05 Risk factors

What could still matter

Stale ticker or quote risk

High impact · Medium odds

Merck says it completed the Verona acquisition on October 7, 2025, and Verona became a wholly owned subsidiary. That means any live-looking VRNA quote may be stale, synthetic, or from an old data feed rather than a normal tradable common stock.

We watchCheck whether VRNA ADSs are listed on Nasdaq and whether a broker allows real trading in the security.

Deal record mismatch

Medium impact · Low odds

Verona's last filing in the audit trail framed the Merck transaction as pending and expected to close in Q4 2025. Later public sources say it closed. The page therefore treats the deal close as current context, while keeping the filing-based thesis history clear.

We watchLook for the Merck closing release, Nasdaq delisting notice, and any court scheme completion notice.

Nuance Pharma rights dispute

Medium impact · Medium odds

Verona told Nuance Pharma in June 2025 that it planned to buy back the Greater China license. Nuance disputed the notice and asked Verona to withdraw it. An unfavorable outcome could affect the value or control of Ohtuvayre rights in that region.

We watchWatch for settlement terms, arbitration updates, or Merck comments on Greater China commercialization rights.

Ohtuvayre launch durability

Medium impact · Medium odds

Ohtuvayre sales rose quickly through Q2 2025, but the product had only been on the U.S. market since August 2024. If patient demand, doctor use, payer coverage, or refill rates faded, the long-term value to Merck would be lower than the early ramp suggested.

We watchTrack Merck respiratory sales comments and any disclosed Ohtuvayre prescription or revenue trends.

Single-molecule concentration

Medium impact · Medium odds

Verona's approved product and pipeline were all built around ensifentrine. That focus made the company easy to understand, but it also meant any safety issue, competitive pressure, or clinical setback could hit most of the value at once.

We watchWatch FDA safety updates, COPD guideline changes, and trial readouts for ensifentrine combinations or new indications.
06 Quick answers

In one breath

Does Verona Pharma still trade as VRNA?

Merck says it completed the acquisition of Verona on October 7, 2025. Verona became a wholly owned subsidiary, and its ADSs no longer trade on Nasdaq.

What was Verona Pharma's main drug?

Verona's main drug was Ohtuvayre, also called ensifentrine. It is an inhaled COPD maintenance treatment for adults and was approved by the FDA on June 26, 2024.

Why did Merck buy Verona Pharma?

The main reason was Ohtuvayre. The drug had a fast early launch, including $102.9 million of net product sales in Q2 2025, and it added a first-in-class COPD product to Merck's portfolio.

What is the Nuance Pharma dispute?

Nuance Pharma held Greater China rights under a licensing deal. In June 2025, Verona said it would exercise its option to buy back those rights, and Nuance disputed the notice.